Top 5 Women’s Health Headlines – September 2025
“`html
Women’s Health Headlines: September 2025 Recap
September 2025 brought a wave of crucial updates that continue to shape the care of women across all stages of life.
In the ever-evolving field of obstetrics and gynecology, noteworthy advancements emerged in maternal-fetal medicine, reproductive endocrinology, oncology, and more.
In this monthly recap, Contemporary OB/GYN highlights the most impactful regulatory news, clinical research findings, and expert perspectives from september 2025.
Click on each title below for in-depth coverage of these key updates.
Hyperemesis Gravidarum and Mental Health Risks
Hyperemesis gravidarum (HG) is associated with substantially increased risks of neuropsychiatric and mental health disorders, according to a retrospective cohort study of 476,857 pregnant women using data from the TriNetX Global Collaborative Network across 18 countries.researchers identified over a 50% increased risk for 13 outcomes, including postpartum psychosis, PTSD, and a twofold higher risk of Wernicke’s encephalopathy, eating disorders, and depression. Postpartum depression was especially elevated, with a 2.7-fold increased risk. Outcomes did not differ by HG severity based on metabolic disturbance, suggesting all patients with HG warrant early mental health support. Investigators emphasized the need for integrated care addressing both physical and psychiatric risks in affected patients.
Elinzanetant for Vasomotor Symptoms
Elinzanetant significantly reduced vasomotor symptoms (VMS) in postmenopausal women, according to results of the phase 3 OASIS-3 trial published in JAMA Internal Medicine. Among 628 participants randomized to elinzanetant 120 mg or placebo for 52 weeks, elinzanetant achieved a 73.8% reduction in moderate to severe hot flashes and night sweats by week 12 compared with 47% in the placebo group. benefits included improved sleep and menopause-specific quality-of-life.